Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.

Christine Chevreau(Institut Claudius Regaud), Sylvie Négrier(Université Claude Bernard Lyon 1), Alain Ravaud(Bordeaux Population Health), Bernard Escudier(Institut Gustave Roussy), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Céline Ferlay, N. Lignon, Robert Hervé, Emmanuelle Blanc, R. Delva, Armelle Caty, F. Rolland(Institut de Cancérologie de l'Ouest)

Journal of Clinical Oncology

May 20, 2011

10.1200/jco.2011.29.15_suppl.4625

Cited by 7

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

|Science|2017|5.4k

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

|New England Journal of Medicine|2018|4.6k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

|New England Journal of Medicine|1998|969

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645